biotech

港股今日表现平平，但创新药概念集体走强！康希诺生物暴涨16%，金斯瑞生物科技涨8.4%，石药集团、恒瑞医药均涨超5%。看来资金正从科技板块流向生物医药，健康科技板块迎来上涨潮。

Hong Kong stocks had a flat day today, but innovative pharma concepts surged! Kangxin Bio jumped over 16%,金斯瑞生物科技 gained 8.4%, and 石药集团、恒瑞医药 all rose more than 5%. Seems like capital is flowing from tech sectors to biomedicine, with health tech seeing a rally.

#Biotech #HealthcareInnovation
$BTC $MANA

逢时科技启动上市辅导啦！这家做南极磷虾生物制品的创新企业要登陆资本市场了，海洋科技领域又添新力量！#生物科技 #海洋科技 $OCEAN

Fengshi Tech just kicked off IPO prep! This innovative company focusing on Antarctic krill biotech products is heading to the capital markets. Ocean tech sector just got stronger! #Biotech #MarineTech $OCEAN

脑胶质瘤有救了！海思科创新药获突破性治疗认定，加速上市！🚀🧠 医药创新+区块链结合才是王道，$MED这类医疗代币值得关注！#生物科技 #DeFi

Brain tumor treatment breakthrough! Haisco's drug gets fast-track approval. 🚀🧠 Pharma innovation + blockchain = future goldmine. Keep an eye on $MED! #Biotech #DeFi

$BIO

The price is trading around 0.0326 USDT, continuing the decline after a strong momentum in mid-April. The short MA is below the long one - the structure remains bearish. The MACD shows negative momentum, the histogram is red, confirming the weakness of buyers.

#BİO #Biotech #TradingTales

$BIO

BIO is doing exactly what a healthy trend does – keeping buying activity right near the support level. Each dip is defended faster than the previous one, and the structure has never been broken. Volume is increasing imperceptibly.

A break could open the way for an upside move, and the risk-reward ratio is clean from here.

Do you support the bid or wait for a breakout?

#BIO #BİO #Biotech

🚨🦟 $GOOGL -BACKED MOSQUITO RELEASE? THE INTERNET IS PANICKING... BUT HERE'S WHAT THEY'RE NOT TELLING YOU 👀👇

32 MILLION mosquitoes could be released in parts of the U.S. 🇺🇸

Sounds terrifying, right? 😳


But before you imagine swarms of mutant insects taking over cities... there's a twist. 🧵👇

🔬 A project backed by Alphabet (Google's parent company) through its health-tech initiative is supporting a mosquito-control program designed to fight dangerous diseases.

The mission? 🎯

✅ Reduce dengue fever cases ✅ Help combat Zika virus outbreaks ✅ Lower West Nile virus transmission ✅ Reduce dependence on chemical pesticides

Here's where things get interesting... 👀

❌ These mosquitoes are NOT released to bite people. ❌ They're NOT part of a "mosquito invasion." ❌ The released mosquitoes are MALES.

And male mosquitoes don't bite humans. 🦟🚫

Instead, they carry a naturally occurring bacterium called Wolbachia.

When they mate with wild female mosquitoes:

📉 Eggs fail to hatch 📉 Mosquito populations gradually decline 📉 Disease-carrying mosquito numbers can be reduced over time

💡 Why are scientists exploring this?

Because some mosquito species are becoming increasingly resistant to traditional pesticides.

Rather than spraying more chemicals, researchers are testing biological solutions that may have a smaller environmental footprint. 🌎

🤔 The bigger question:

If biotechnology could significantly reduce the spread of deadly mosquito-borne diseases...

Would YOU support releasing millions of non-biting mosquitoes? 👇

🔥 YES — if it saves lives 😬 NO — too many unknown risks

Drop your answer below and let's discuss! 💬
$STRAX

#Technology | #Biotech | #NomuraOCCTrustBankApproval | #STRAX | #SoulThunder

📚 Sources: (US EPA Experimental Use Permit Notice, CDC Wolbachia Program, World Mosquito Program, USA Today Network Reporting)

Moderna and Merck’s mRNA cancer vaccine meets Phase 3 endpoints, sending Moderna shares sharply higher

🧬 Moderna and Merck said their personalized mRNA vaccine, intismeran autogene, combined with Keytruda met both the primary recurrence-free survival endpoint and the key secondary distant metastasis-free survival endpoint in the Phase 3 INTerpath-001 trial involving 1,137 patients with surgically resected melanoma.

📈 The result marks the first Phase 3 success for an mRNA-based cancer therapy and an individualized neoantigen vaccine, reinforcing the positive signal previously seen in the Phase 2b study.

💹 Market reaction was strong, with Moderna shares rising around 90–100%+ in premarket trading, while Merck gained roughly 6–9%.

⚠️ However, detailed data such as the hazard ratio and absolute benefit have not yet been released, while overall survival remains under follow-up. The longer-term impact will depend on the full dataset and regulatory progress.

#Biotech $MRNAon $MRK.US $BNB

🚨 $MRNA
— CANCER VACCINE MILESTONE

$MRNA has more than doubled since mid-August, fueled by the Moderna–Merck cancer vaccine Phase 3 success.

🔥 This marks a major milestone: the first Phase 3 efficacy readout for a therapeutic cancer vaccine.

📈 The move highlights how powerful clinical breakthroughs can be for biotech valuations.

👀 $MRNA remains one to watch as the market continues to price in the potential impact of this breakthrough.

#MRNA #Biotech #CancerVaccine #StocksToBinance

The biggest wealth transfer in crypto won't come from finance. It will come from biology.

Everyone is fighting over decentralized exchanges and yield farming, while a massive capital rotation is quietly happening in Decentralized Science. The DeSci super-cycle is officially here.

The traditional scientific funding model is a slow, bureaucratic nightmare. Brilliant researchers spend years begging centralized institutions for grants, while massive pharmaceutical monopolies lock life-saving patents behind closed doors.

Blockchain infrastructure is completely restructuring this system.

Through IP-NFTs, scientific research and medical patents are being tokenized on-chain. This means retail investors can directly fund early-stage biotech, longevity research, and rare disease treatments.

If a decentralized research collective discovers a new chemical compound and licenses the intellectual property to a major pharma company, the token holders who funded the research capture the actual financial upside. You are no longer just betting on a software application; you are investing in the legal rights to medical progress.

The transition from DeFi to DeSci is opening up venture-capital-level biotech opportunities to anyone with a crypto wallet.

$NMR $RIF $BIO
#Write2Earn #DeSci #Biotech #CryptoTrends

📈 #ModernaRisesOver12% — Biotech Giant Surges on New Pipeline Data

Moderna shares jumping over 12% after positive clinical trial data for its next-generation mRNA vaccine pipeline. Investors piling back into biotech as Moderna demonstrates progress beyond COVID-19 vaccines.

#ModernaRisesOver12% #Biotech #MRNA

$BIO

Trading volumes remain stable, without sharp sales spikes. The structure indicates the formation of higher lows and higher highs. Buyers are actively defending the entry zones, not allowing prices to fall. In the event of a resistance breakdown, the momentum can accelerate significantly.

#BIO #BİO #Biotech

🚨 $XBI
USDT Perp is almost live on Binance Futures 🚨

Another fresh listing is about to hit the board — XBIUSDT Perpetual is counting down and the market is getting ready. 👀🔥

Pair: XBIUSDT Perp
Underlying asset: SPDR S&P Biotech ETF (XBI)
Platform: Binance Futures
Status: Pre-launch / trading not open yet
Countdown shown: 01 Hour 25 Min 44 Sec remaining at the time of screenshot

Right now, price and market stats are still inactive:

Last Price: 0.00

Mark Price: 0.00

24h High / Low: 0.00 / 0.00

24h Volume: 0.00

That usually means the contract page is live before actual trading starts, giving traders time to prepare for the opening volatility. Since XBI tracks the biotech sector, this launch is interesting because it brings a traditional biotech ETF exposure into perpetual futures trading format.

What to watch at open:

First few candles for volatility spike

Funding and liquidity behavior

Early long/short battle after listing goes live

Binance is opening the door for biotech-linked perp action — XBIUSDT could get very wild right after launch. 📈⚡
#Binance #Futures #XBIUSDT #Perpetual #CryptoTrading #Biotech
ParadigmRaises$1.2BThirdFundForAIAndRobotics

#FedMinutesShowSplitOnRateHikes
#SonyGetsOCCApprovalForStablecoinTrust
#KOSPIJumpsNearly4%To7539
#SKHynixUSListingOversubscribed7x

Parabilis raises 670M in record biotech IPO, signaling renewed risk appetite in healthcare innovation

🧬 Parabilis Medicines began trading on Nasdaq under the ticker PBLS after selling 33.5 million shares at 20 USD per share, raising around 670 million USD through its IPO. The size of the deal makes it one of the most notable biotech listings of 2026.

🏛️ The key point is not only the capital raised, but also the fact that the offering was upsized while the biotech IPO market remains selective. This suggests investors are still willing to back companies with differentiated technology, clear clinical programs and strong long-term potential.

🤝 Regeneron also joined a concurrent private placement of around 75 million USD and had already entered a strategic collaboration with Parabilis in May. The involvement of a major pharmaceutical name adds more attention to Helicon, Parabilis’ peptide platform designed to reach intracellular targets that traditional drugs often struggle to address.

🔬 The new funding will support the development of zolucatetide, the company’s lead program targeting desmoid tumors and other cancers linked to the Wnt/β-catenin pathway. Parabilis aims to move this program closer to Phase 3 development in 2027.

⚖️ Despite the positive IPO narrative, Parabilis remains a clinical-stage biotech company with meaningful trial risk. After the initial listing phase, clinical data, pipeline execution and institutional demand will matter more than the headline IPO size.

#Biotech $BTC $BNB $HNT

$BIO
The dominant structure is a long-term descending channel/trendline:

• Major high around $0.06–0.065
• Successive lower highs afterward
• Price is now around $0.0247
• The large descending resistance is still overhead.

So the chart has not yet confirmed a full trend reversal. What it has done is establish a potentially important base around $0.021–0.022.

Bullish scenario
A daily close above approximately $0.027 would be the first meaningful structural improvement.
If that happens and volume expands, the next areas to watch are roughly:

$0.030 → $0.035 → $0.045

The $0.035 region is particularly important because it corresponds to the previous breakdown/consolidation area.
The really important reversal confirmation would ultimately be a break of the large descending trendline, not merely a move from $0.025 to $0.030.

#Biotech

$BIO is gaining some solid attention today.The token has been showing decent volume and steady buying interest. With its focus on decentralized biotechnology, longevity, and health data, $BIO is becoming one of the more unique and promising projects in the BioTech x Crypto space.Many traders are now watching if it can break its recent resistance and move higher.Are you holding $BIO or planning to enter on this move?
Drop your thoughts #BIO #BioTech

The operating room of the future may look very different from the one we know today.

Some surgeries are already limited by something very human: the precision of our hands.

Microsurgery can involve blood vessels and nerves smaller than 1 millimeter. Even the best surgeons still face natural tremor, fatigue and restricted movement in deep or difficult areas of the body. New robotic microsurgery systems are being developed to reduce those limitations through motion scaling and tremor filtration. Recent clinical research shows that these systems can already improve precision in extremely delicate procedures.

Now imagine what happens when #Robotics becomes smaller, more precise and combined with artificial intelligence.

The first major step will probably not be robots replacing surgeons.

It will be robots helping surgeons see more clearly, recognize anatomy, detect possible errors and perform movements that are difficult for the human hand. Current research suggests AI assisted surgical systems could improve perception and intraoperative guidance while keeping the surgeon in control.

Further ahead we may see microrobots operating inside parts of the body that are extremely difficult to reach today. Researchers are already studying autonomous robotic surgery and microrobotic surgery as long term directions.

For crypto there is also an interesting connection.
Projects such as $BIO are building blockchain based infrastructure around biotechnology research and decentralized scientific funding. That does not make $BIO a robotic surgery token. But it represents another part of the same future where medical research, funding and technology become more connected.
#Biotech
My view is simple:
The next revolution in healthcare may not come from one new medicine. It may come from giving doctors capabilities the human body never had before.

Will you trust a surgeon using an #AI assisted robot for a procedure that could not be performed safely by hand?

I think I will not :) This makes me so scared.

$METIS 近期基本面出现明显变化：生态侧完成 AI Agent 升级，链上叙事被重新激活；商业侧子公司 Metis TechBio 敲定 16 亿美元药物授权协议，把项目和真实现金流拉到了同一张桌上。

现价约 2.73 美元，24 小时成交 215 万美元，市值仅 2061 万美元，属于典型的小盘高弹性区间。技术升级带来使用场景，生物科技合作带来信心背书，两条线在同一时间点共振，是这轮走强的核心逻辑。

不过要提醒的是，流动性偏薄意味着双向波动都会被放大，追高前建议先看盘口深度，把仓位和止损写在进场之前，而不是行情走坏之后。

#Metis #AIAgent #BioTech

ALERT 🚨 Bullish momentum builds for $SCRT (SECRET) as order blocks surface above the 200 day volume 📈. $NVDAB (NVIDIA) pushes innovation in AI, boosting liquidity and investor sentiment 💡. $BIO (BIO) rides biotech ecosystem growth, tightening trading activity 🧪. Strong buy across the trio. #SecretNetwork #NVIDIA #Biotech